Browse LGALS3BP

Summary
SymbolLGALS3BP
Namelectin, galactoside-binding, soluble, 3 binding protein
Aliases MAC-2-BP; 90K; BTBD17B; TANGO10B; M2BP; gp90; CyCAP; L3 antigen; Mac-2-binding protein; serum protein 90K; t ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Secreted Secreted, extracellular space, extracellular matrix
Domain PF07707 BTB And C-terminal Kelch
PF00530 Scavenger receptor cysteine-rich domain
Function

Promotes integrin-mediated cell adhesion. May stimulate host defense against viruses and tumor cells.

> Gene Ontology
 
Biological Process GO:0002576 platelet degranulation
GO:0006887 exocytosis
GO:0006898 receptor-mediated endocytosis
GO:0006968 cellular defense response
GO:0045055 regulated exocytosis
Molecular Function GO:0005044 scavenger receptor activity
GO:0038024 cargo receptor activity
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0030141 secretory granule
GO:0031089 platelet dense granule lumen
GO:0031983 vesicle lumen
GO:0034774 secretory granule lumen
GO:0042827 platelet dense granule
GO:0060205 cytoplasmic membrane-bounded vesicle lumen
GO:0072562 blood microparticle
GO:0099503 secretory vesicle
> KEGG and Reactome Pathway
 
KEGG -
Reactome R-HSA-109582: Hemostasis
R-HSA-76002: Platelet activation, signaling and aggregation
R-HSA-114608: Platelet degranulation
R-HSA-76005: Response to elevated platelet cytosolic Ca2+
Summary
SymbolLGALS3BP
Namelectin, galactoside-binding, soluble, 3 binding protein
Aliases MAC-2-BP; 90K; BTBD17B; TANGO10B; M2BP; gp90; CyCAP; L3 antigen; Mac-2-binding protein; serum protein 90K; t ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between LGALS3BP and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 
  Literatures describing the relation between LGALS3BP and anti-tumor immunity in human cancer.
PMID Cancer type Relation to immunity Evidence sentences
25315772Colorectal Carcinoma; Prostate CarcinomaInhibit immunityThese findings suggest a novel immunoinhibitory function for LGALS3BP that might be important for immune evasion of tumor cells during cancer progression.
20581239Colorectal CarcinomaPromote immunitySecreted 90K suppresses CRC cell invasion, but this action of 90K is masked through binding with extracellular galectins. In a syngeneic mouse colon tumour model, tumour growth and lung metastasis were increased with 90K knockdown. 90K itself has antitumour activity in CRC cells via suppression of Wnt signalling with a novel mechanism of ISGylation-dependent ubiquitination of beta-catenin when it interacts with CD9/CD82, but is downregulated in advanced CRC tissues.
16204073Colon AdenocarcinomaPromote immunityOverexpression of 90K in CT-26/antisense KITENIN cells further delayed tumor growth compared with that of CT-26/antisense KITENIN cells.
Summary
SymbolLGALS3BP
Namelectin, galactoside-binding, soluble, 3 binding protein
Aliases MAC-2-BP; 90K; BTBD17B; TANGO10B; M2BP; gp90; CyCAP; L3 antigen; Mac-2-binding protein; serum protein 90K; t ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of LGALS3BP in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolLGALS3BP
Namelectin, galactoside-binding, soluble, 3 binding protein
Aliases MAC-2-BP; 90K; BTBD17B; TANGO10B; M2BP; gp90; CyCAP; L3 antigen; Mac-2-binding protein; serum protein 90K; t ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of LGALS3BP in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)14120.3060.504
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)650.1380.973
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)870.4330.883
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.6560.211
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.7030.802
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.5920.864
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.2170.724
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.0360.988
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.270.923
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.2430.927
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 28-0.2640.949
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.0030.979
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of LGALS3BP in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.74.1-0.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.75.1-1.41
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21174.804.81
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160001
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470001
1329033130MelanomaallAnti-PD-1 (nivolumab) 382703.7-3.70.415
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221307.7-7.70.371
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolLGALS3BP
Namelectin, galactoside-binding, soluble, 3 binding protein
Aliases MAC-2-BP; 90K; BTBD17B; TANGO10B; M2BP; gp90; CyCAP; L3 antigen; Mac-2-binding protein; serum protein 90K; t ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of LGALS3BP. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolLGALS3BP
Namelectin, galactoside-binding, soluble, 3 binding protein
Aliases MAC-2-BP; 90K; BTBD17B; TANGO10B; M2BP; gp90; CyCAP; L3 antigen; Mac-2-binding protein; serum protein 90K; t ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of LGALS3BP. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by LGALS3BP.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolLGALS3BP
Namelectin, galactoside-binding, soluble, 3 binding protein
Aliases MAC-2-BP; 90K; BTBD17B; TANGO10B; M2BP; gp90; CyCAP; L3 antigen; Mac-2-binding protein; serum protein 90K; t ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of LGALS3BP. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolLGALS3BP
Namelectin, galactoside-binding, soluble, 3 binding protein
Aliases MAC-2-BP; 90K; BTBD17B; TANGO10B; M2BP; gp90; CyCAP; L3 antigen; Mac-2-binding protein; serum protein 90K; t ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of LGALS3BP expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolLGALS3BP
Namelectin, galactoside-binding, soluble, 3 binding protein
Aliases MAC-2-BP; 90K; BTBD17B; TANGO10B; M2BP; gp90; CyCAP; L3 antigen; Mac-2-binding protein; serum protein 90K; t ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between LGALS3BP and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolLGALS3BP
Namelectin, galactoside-binding, soluble, 3 binding protein
Aliases MAC-2-BP; 90K; BTBD17B; TANGO10B; M2BP; gp90; CyCAP; L3 antigen; Mac-2-binding protein; serum protein 90K; t ......
Chromosomal Location17q25
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting LGALS3BP collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.